ArticleFrontiers in immunology2025
Multi-omics integration identifies NK cell-mediated cytotoxicity as a therapeutic target in systemic lupus erythematosus.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Applications of artificial intelligence in systemic lupus erythematosus: integrating multi-omics data for precision medicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is an autoimmune condition that impacts various organs. Given the intricate clinical progression of SLE, it is imperative to explore novel avenues for precise diagnosis and treatment. Methods: Peripheral blood mononuclear cells (PBMC) were isolated from 6 SLE patients before and after treatment, 7 healthy controls and 7 disease controls. Assay for Transposase Accessible Chromatin with high throughput Sequencing (ATAC-seq) was used to analyze the chromatin accessibility signatures and RNA-seq was used to identify the differentially expressed genes, mRNA, lncRNA, circRNA, miRNA. Then ATAC-seq and RNA-seq were integrated to further analyze hub genes and pathways. Finally, we validated gene expression levels and examined changes in key genes after treatment through Results: Our analysis reveals dynamic changes in chromatin accessibility during the course of disease progression in SLE. Significantly higher numbers of differentially accessible regions, transcripts, genes, mRNA, lncRNA, circRNA, and miRNA were observed in SLE patients compared to other cohorts, with these variances markedly reduced post-treatment. Two gene clusters associated with SLE disease improvement were identified, with a total of 140 genes intersecting with ATAC results. Pathway analysis revealed that NK cell mediated cytotoxicity was the most differentiated and therapeutically altered pathway in SLE patients. Independent sample validation confirmed that the gene expression of this pathway was reduced in SLE patients and associated with disease activity, whereas hydroxychloroquine (HCQ) effectively elevated their expression Conclusion: Our findings suggest that these NK cell signature genes may be associated with the complex pathogenesis of SLE. The restoration of NK cell-mediated cytotoxicity may serve as a useful marker of improvement following SLE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.